The TB Vaccine Evaluation Group uses the non-human primate (NHP) model to assess the safety, efficacy and immunogenicity of a range of novel vaccines and therapeutics to protect against and treat Tuberculosis, a disease that was responsible for 1.4 million deaths in 2019.
You will be involved in the analysis of blood samples to measure the mycobacteria-specific cellular immune response in response to vaccination and/or infection at ACDP Containment Levels 2 & 3 using a range of advanced immunoassays including; the ELISPOT assay, flow cytometry and multiplex bead array technology.
